| Ytd | 49.36% | |
| 1y | 18.27% |
| Open | 2.22 | Prev Close | 2.18 | Low | 2.21 | High | 2.40 | Mkt Cap | 64.67M |
| Vol | 677.64K | Avg Vol | 739.98K | EPS | -0.62 | P/E | N/A | Forward P/E | -2.23 |
| Beta | 1.85 | Short Ratio | 18.08 | Inst. Own | 24.32% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 2.10 | 200-d Avg | 1.63 | 1yr Est | 19.83 |
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilitie
The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fl
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment the
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ i
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ i
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therap
BOCA RATON, Fla. , July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"),
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Re
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Re
The Department of Defense–funded study; entitled: "Inhibition of Soluble TNF Mitigates Traumatic
The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and co
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and co
Submission advances a key element of the Company’s global intellectual property strategy for its nex
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Prog
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path f
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions co
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions co
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0. 0028; d=0. 4
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss a
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
Gainers CynergisTek, Inc. (NYSE: CTEK) shares surged 100% to close at $1.18 on Tuesday after the
Upgrades
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report
During Tuesday's session, 454 stocks hit new 52-week lows.
On Monday, 671 companies achieved new lows for the year.